The United States FDA approved Reyvow a tablet for treating migraine with or without aura in the adults. Reyvow is the first FDA approved medicine in the class of acute migraine treatment. Lasmiditan is a ‘5-HT’ 1F receptor agonist.
Migraine headache pain is an extreme pain in one area of head. Besides the pain, the sufferers of migraine experience sensitivity to light & sound, nausea, and aura. According to the Food and Drug Administration, about one-fourth of people who are sufferers of migraine experience auras ahead of the pain, which can look like zig-zag lines, flashing lights and short-term loss of vision. Migraines can be caused by several factors such as stress, hormonal changes, lack of food and sleep & also diet. Migraine is common in women than in men and affects 10% of people all over the world. The head of neurology development Mr.Gudarz Davar of Lilly Bio-Medicines,said there is a critical unmet need for migraine treatment. Reyvow can help sufferers of migraine with pain & symptoms. The FDA, on October 11, announced that the approval is based on results from pair of randomized, double-blind, placebo-controlled trials that involved 3,177 patients (Adults) with migraine with and without aura. The number of patients whose pain & migraine symptom was resolved after 2 hrs was higher after receiving lasmiditan than ones receiving Placebo. The adverse effects related to lasmiditan include paresthesia, sedation, dizziness, & fatigue. There is a risk of impaired driving while on medication, so the patients are suggested not to operate or drive any machinery for 9 hrs after taking Reyvow (lasmiditan).
The Food and Drug Administration is the agency of the United States Department of Health & Human Services. It safeguards public health by promising the security & safety of human & veterinary drugs, vaccines, and other biological products for use & medical equipment.FDA is also responsible for the safety & security of United States food supply, dietary supplements, cosmetics, products that emit electronic radiation.